INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)
INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
Summary ReportBIOLOGICAL SPECIMENS
2017/1
Samples Substances Concentrations Comments on substances
Sample 1 [blank sample]
Sample 2 Amfetamine 1270 ng/ml
Nordazepam 1960 ng/ml
Oxazepam 570 ng/ml
Temazepam 580 ng/ml
Sample 3 gamma-Hydroxybutyric acid (GHB) 16560 ng/ml
Sample 4 Morphine 860 ng/ml
Test Samples Information
Samples Comments on samples
Sample 1 BS-1 was a blank urine test sample containing no substances from the ICE menu.
Sample 2 To prepare BS-2, urine was spiked with an aqueous solution of amfetamine sulphate (1270ng base/ml) and methanol solutions of nordazepam (1960ng base/ml), oxazepam (570ng/ml) and temazepam (580ng/ml). The spiked urine was dispensed in 50ml aliquots and lyophilised.
Sample 3 To prepare BS-3, urine was spiked with an aqueous solution of gamma-hydroxybutyric acid (GHB) (16560ng/ml). The spiked urine was dispensed in 50ml aliquots and lyophilised.
Sample 4 To prepare BS-4, urine was spiked with an aqueous solution of morphine sulphate (860ng base/ml). The spiked urine was dispensed in 50ml aliquots and lyophilised.
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
Table of contents Introduction Page 2
Comments from the International Panel of Forensic Experts Page 2
NPS reported by ICE participants Page 4 Codes and Abbreviations Page 6
Sample 1 Analysis Page 7 Identified substances Page 7 Statement of findings Page 8 Identification methods Page 11 Summary Page 14
Sample 2 Analysis Page 15 Identified substances Page 15 Statement of findings Page 18 Identification methods Page 23 Summary Page 26 Z-Scores Page 27
Sample 3 Analysis Page 37 Identified substances Page 37 Statement of findings Page 39 Identification methods Page 44 Summary Page 47 Z-Scores Page 48
Sample 4 Analysis Page 51
Identified substances Page 51 Statement of findings Page 54 Identification methods Page 59 Summary Page 62 Z-Scores Page 63
2
IntroductionAn important element of the UNODC International Quality Assurance Programme (IQAP) is the implementation of the International Collaborative Exercises (ICE). The exercises allow laboratories, from both developing and developed countries, to continuously monitor their performance in drug testing on a truly global scale. This report provides information on analytical results of laboratories participating in the Biological Specimens (BS) group. In order to maintain confidentiality, the participating laboratories have been assigned random “Web Codes”, which change every round. The analytical results returned by laboratories participating in ICE are evaluated by UNODC and a confidential report is provided to each laboratory on its own performance. The overall analytical results are reviewed by the UNODC’s International Panel of Forensic Experts which oversees the implementation of these exercises, and offers guidance and support in addressing relevant quality issues. The exercises provide an overview of the performance and capacity of participating laboratories and enable UNODC to tailor technical support in the laboratory sector for greatest impact.
Comments from the International Panel of Forensic Experts
Participation of Laboratories
In the 2017/1 round of the ICE programme, results were submitted within both the Seized Materials (SM)and Biological Specimens (BS) test groups by 238 laboratories in 76 countries. Within the SM test group, there were 201 participating laboratories from 68 countries and within the BS test group, results were submitted by96 laboratories from 45 countries.
Qualitative Analysis
The analytical technique most commonly used for screening of test samples in the BS test group were enzyme immunoassays (56% of participants), while GC-MS (84%) was the most commonly used technique for identification/confirmation of the components in the test samples. The results for the qualitative identification of the sample components in the BS test group, the number of false positive/negative results and the analysesnot performed are shown in table 1.
Table 1. Qualitative performance of participants in the 2017/1 round of ICE.
Test sample BS-1 BS-2
(Amfetamine) BS-2
(Nordazepam) BS-2
(Oxazepam) BS-2
(Temazepam) (Blank)
Correct identification
99% 88% 94% 63% 75%
Number of false positives
1 7
Number of false negatives
- 0
Number of analyses not
performed (ANP) - 3
Test sample BS-3 BS-4
(GHB) ( Morphine )
Correct identification
34% 88%
Number of false positives 7 10
Number of false negatives
14 4
Number of analyses not
performed (ANP) 49 6
Laboratories reporting false positive or false negative results should investigate the reasons for this and corrective actions should be taken in order to continuously improve performance. ICE participants are reminded that test samples can contain any of the substances in the ICE menu and as such if methods are available, all substances should be considered.
3
Quantitative Analysis
The test samples in the BS group for the 2017/1 round of ICE contained a total of six components and 43(46%) of participating laboratories performed quantification. Of these laboratories, it is encouraging to note that 93% of laboratories quantified at least two components and 37% performed quantification of all components present. GC-MS was used by 49% of participants for quantification, followed by LC/MS(/MS), which was used by 33% of participants. z-scores obtained by participants in quantification are shown in thetable below (percentage + no. of labs indicated).
Table 2. Quantitative performance of participants in the 2017/1 round of ICE.
z-score
Test sample
BS-2 (Amfetamine)
BS-2 (Nordazepam)
BS-2 (Oxazepam)
|z| < 2, satisfactory 86% (31) 82% (23)
2 ≤ |z| ≤ 3, questionable
6% (2) 4% (1)
|z| > 3, unsatisfactory
86% (31)
6% (2)
8% (3) 8% (3) 14% (4)
z-score BS-2 (Temazepam) BS-3 (GHB) BS-4 (Morphine)
|z| < 2, satisfactory 77% (28) 84% (16) 77% (30)
2 ≤ |z| ≤ 3, questionable
6% (2) 5% (1) 13% (5)
|z| > 3, unsatisfactory
3% (1) 11% (2) 10% (4)
According to the recommendations in ISO 13528:2005, an unsatisfactory z-score is considered to give an action signal and a questionable z-score is considered to give a warning signal. A single action signal or warning signals in two successive rounds shall be taken that an anomaly has occurred that requires investigation. Participants with z-scores outside acceptable limits should review their quantification procedures.
In the 2016/2 round of ICE, ten laboratories obtained questionable z-scores with 2 ≤ |z| < 3. Eight of these laboratories participated and performed quantification in the 2017/1 round with six laboratories improving their performance in quantitation for at least one substance. Four of these laboratories also obtained questionable z-scores and five of these laboratories also obtained unsatisfactory z-scores in their quantitative performance in 2017/1. Nine laboratories obtained unsatisfactory z-scores in ICE 2016/2 with |z| ≥ 3. Of these laboratories, five participated in ICE 2017/1 and performed quantification, with 4 (80%) improving their performance to obtain satisfactory z-scores. Three of these laboratories also obtained questionable z-scores and two of these laboratories also obtained unsatisfactory z-scores in their quantitative performance in 2017/1.
The following laboratories obtained a single action signal or warning signal in the two successive rounds of 2016/2 and 20167/1 and shall take this as anomaly, which requires further investigation: UTSOWL,3FMD3X, 8MFF1T, AMMRSO, DDA5D2, IQJAM7, NDP7T7 and VLHXHH.
Laboratories that need to perform quantitation routinely are encouraged to participate regularly in external proficiency testing or collaborative exercises such as the ICE programme. This will enable laboratories to assess the quality of their quantitative methods through the z-score values obtained. Laboratories reporting false positive or false negative results should investigate the root causes and corrective actions taken promptly in order to continuously improve performance. Participation in the ICE programme also helps in monitoring the effect of corrective actions. UNODC would like to acknowledge the valuable contribution of the Chemical Metrology Laboratory of the Health Sciences Authority, Singapore, for the provision of specific software used for the quantitative statistical calculations in the ICE programme.
4
New Psychoactive Substances (NPS) reported by laboratories participating in the 2017/1 round of the ICE programme. During the 2017/1 round of ICE, participating laboratories provided information on NPS that had been identified in their laboratories. In total there were 148 reports of 93 substances. The most commonly reported substances were synthetic cathinones (36%) followed by synthetic cannabinoids (25%) as shown in figure 1.
Figure 1. NPS reported by ICE laboratories during the 2017/1round of ICE
In terms of the mode of action of the NPS reported by ICE participants, the predominant substances reported were stimulants (50%), while 16% were synthetic cannabinoid receptor agonists (SCRA’s) and 13% were synthetic opioids as shown in figure 2.
Figure 2. Mode of action of NPS most commonly reported by ICE participants in the 2017/1 round of ICE
25%
36%
23%
8%
5% 3%
Synthetic cannabinoids
Synthetic cathinones
Others
Phenethylamines
Ketamine and phencyclidinetype substances
Tryptamines
50%
16%
13%
11%
8%
2%
Stimulants
SCRA's
Opioids
Hallucinogens
Dissociatives
Sedatives/Hypnotics
5
NPS most commonly reported by laboratories participating in ICE 2017/1.
The substance most often reported by ICE participants was the synthetic cathinone ephylone (N- ethylpentylone) followed by the synthetic opioid U-47700 (3,4-dichloro-N-((1S,2S)-2-(dimethylamino)cyclohexyl)-N-methylbenzamide). This is the first time a synthetic opioid has been among the substances most reported by ICE participants. U-47700 was placed under International Control(Schedule I of the Single Convention on Narcotic Drugs of 1961) at the 2017 Meeting of the Commission on Narcotic Drugs. The decision became effective on 22 April 2017.
For further details on these substances and others reported to the UNODC Early Warning Advisory, ICE participants can log on to the UNODC ICE portal and select the icon for the Early Warning Advisory on New Psychoactive substances as shown below. https://www.unodc.org/LSS/Home/ICE
6
Codes and Abbreviations
Tech Code Name
100 Agglutination Techniques
110 Enzyme Immunoassay Techniques
120 Fluorescence Polarization Immunoassay
130 Radioimmunoassay
140 Colorimetric reactions
141 Marquis reagent (sulphuric acid, formaldehyde)
142 Cobalt thiocyanate
150 Thin Layer Chromatography
160 High/Ultra High Performance Liquid Chromatography
161 High Performance Liquid Chromatography with diode array detection
170 Gas Chromatography NPD
171 Gas Chromatography FID
172 Gas Chromatography ECD
180 Gas Chromatography/Mass Spectrometry
190 Fourier Transform Infrared Spectrometry
200 Spectrophotometry (visible, UV)
210 Others (specify)
211 NMR
220 Microcrystal test
230 Liquid chromatography/mass spectrometry
231 Liquid chromatography/tandem mass spectrometry
(+) “positive”: Indicates that the analyte is identified; for presumptive tests (e.g. colour reactions), indicates that a positive reaction was obtained.
(-) “negative”: Indicates that the analyte is not identified.
(ANP): Analysis not performed.
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
67
Identified substances for Test Sample 1
Code Identified Substances3FMD3X GHB
8LCBAB none
AMMRSO no found
DDSBTD -
DFYDDD None
GBGZ1G NA
GNAW99 Unknown
GUGPPP not detected
HVHHFH No found drugs
KHJBOK no
MXA7O5 no
NDP7T7 none
OOO3GD /
PCBAPT no drugs found
Q4WQSQ Not present
QZEZZZ -
T0B0D0 None
TTTGKV None
USDN2N NONE
UUXUUM NO
WEB9SQ Abs
WZUJSD -
XNXEE6 NO FOUND
Z4YCUT NONE
ZGAWTE Not detected.
Sample 1 Analysis
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
78
Code [blank sample]
0H72WR Drugs Not Detected
1111EF
1A3AXJ
35TZAW
3FMD3X GHB was detected in sample BS1 2017/1.
4FF58F
66OQY6
6V10VI
7BVRLF
7FEMIN
84HKVU
8LCBAB We did not find any drugs. We found only caffein.
8MFF1T
8TPBUN
8VX7GU
AG3666
AMMRSO no drugs found in the sample 2017/1/BS-1
B1KV8H
BBKEUE
BHWJHB
BNGG0M
CPUSPP
CTTCT3
D1AYDM Not detected.
DB4Y6M BLANK
DDA5D2 Negative
DDSBTD -
DFYDDD In Sample 2017/1/BS-1 no drug was found
DHUDIC The substances that were tested for weren´t found to be present in the sample analysed.
DQMUDL
EPEVE2 Sample contains no substances from ICE menu
FBYTRU No common drugs were detected in sample 2017/1/BS-1
FWXVWL
GAHHTQ
GBGZ1G Sample was negative during screening for all drug groups tested at our laboratory. Creatinine levels were satisfactory.
GMUMBE Negative
GNAW99 We found two stain in TLC plate for this sample but because we did not have all of the refrences we could not identify them.
Statement of findings for Test Sample 1
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
89
Code [blank sample]
GUGPPP blank
GXJGYM a preliminar screenning by EIA with no possitive results
H2PHCD
HB4JKY
HHLH88 Performed by GS/MS Method and Caffeine was found.
HVHHFH Sample code number 2017/1/BS-1 was found doesn't contain controlled drugs.
IJS22F
IQIQAI Common drugs not detected.
IQJAM7
IVV5RV (remark :caffeine present)
JRKD4U THE SAMPLE BS-1 ANALYZED DOES NOT CONTAINS CONTROLLED DRUGS ( AMPHETAMINE, BENZODIAZEPINES,COCAINE/METABOLITES,OPIATES,11-NOR-DELTA9-THC-9-CARBOXYLIC ACID,BARBITURATES.
JSZABT No proof of drug abuse.
K3KSJ9
KHJBOK
KJPKK4
L3ZOZH
LJTLFH
M8VO1Z
MXA7O5 blank sampke
NCMGK4
NDP7T7
NGAJ1Y
NP5333
OOO3GD no drugs were found
PCBAPT caffeine, ibuprophen
PQFUYI
PXJDZ1
Q4WQSQ Screening test, GC/MS: Not to be present
QZEZZZ -
RNJJ8Z
SOK66J
SV8SSS
SZZ1BZ Negative.
T0B0D0 Sample 2017/1/BS-1 found not to contain any drugs
TBORSX
TG33JW
TISIQZ Negative the screening method
TTTGKV No control drugs found
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
910
Code [blank sample]
U5KOOL
UCTGCC
UIUDEC No drug was found in the sample number 1
USDN2N
UTSOWL
UUXUUM No drugs or controlled drugs detected
V6ZRMH
VLHXHH after analysis performed the sample contained caffeine
VN2UVV Drugs were not detected in BS-1 sample
VR1QQH The urine screen did not indicate the presence of any of the targeted drugs.
W5TXOT No controlled drugs of the ICE 2017/1 menu were detected in the test sample 2017/1/BS-1.
WEB9SQ
WZRRBA Examination of the sample coded 2017/1/BS-1 did not reveal the presence of any controlled drugs
WZUJSD negative
XNXEE6 NO FOUND
Y3AFEE
YFYCWJ No se detectó
YGKDY2 No controlled drug from ICE 2017/01 menu is detected
YSKXXD No drugs were found in this sample.
Z4YCUT
ZGAWTE Not detected drugs into 2017/1/BS-1 sample by Enzyme Immunoassay Techniques (EIA) and by Gas Chromatgraphy/Mass Spectrometry (CG/MS).
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
1011
Identification methods for Test Sample 1
Code 100 110 120 140 141 150 160 161 170 180 230 231 210
0H72WR I
1111EF I I
1A3AXJ I S chemical immunochromatographic
35TZAW S I I
3FMD3X I SI S Dip test
4FF58F S I LC/QTOF
6V10VI S I I
7BVRLF S SI I
7FEMIN S I I
84HKVU SI I S Multi-Drug Screen Test Panel
8LCBAB I SI Dipro drug lab screen
8MFF1T S I
8TPBUN I SI I
8VX7GU S I I SI Kinetic Interaction of Microparticles in Solution
AG3666 S I
AMMRSO S SI S I
B1KV8H S I I
BBKEUE S I I
BHWJHB S SI S LC-QTOF
BNGG0M S I
CPUSPP S I I
CTTCT3 I I S inmunocromatografía flujo lateral
D1AYDM S I SI
DB4Y6M S I
DDA5D2 S SI SI
DDSBTD S SI I
DFYDDD SI SI
DHUDIC S I
DQMUDL I LC/TOF
EPEVE2 S SI S LC-TOF
FBYTRU SI
FWXVWL S SI I
GAHHTQ S SI I
Analytical Technique Codes
Legend: S ... used for Screening I ... used for Identification SI ... used for both
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
1112
Code 100 110 120 140 141 150 160 161 170 180 230 231 210
GBGZ1G S I
GMUMBE S SI
GNAW99 SI
GUGPPP SI
GXJGYM S I I LC-QTOF
H2PHCD I
HB4JKY S I
HHLH88 S I
HVHHFH SI I
IJS22F S I
IQIQAI S I
IQJAM7 S I
IVV5RV I I SI
JRKD4U SI SI
JSZABT I I S
K3KSJ9 S I
KHJBOK I I
KJPKK4 I S zivia kit multitest
L3ZOZH S I
LJTLFH S I
M8VO1Z S I SI
MXA7O5 SI
NCMGK4 SI
NDP7T7 I I S immunochromatographie
NGAJ1Y S I
NP5333 S SI
OOO3GD S I I
PCBAPT S I I
PQFUYI SI SI I
PXJDZ1 SI I I
Q4WQSQ S I
QZEZZZ SI
RNJJ8Z S I
SOK66J S I I
SV8SSS I SI
SZZ1BZ S I
T0B0D0 SI
TBORSX S I
TG33JW S I I
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
1213
Code 100 110 120 140 141 150 160 161 170 180 230 231 210
TISIQZ SI SI
TTTGKV S S I I
U5KOOL S I I
UCTGCC S I I
UIUDEC S I
USDN2N I
UTSOWL I I Triage 8- ALERE Sure Step
UUXUUM SI I
V6ZRMH S I SI
VLHXHH S I
VN2UVV S I
VR1QQH SI
W5TXOT SI
WEB9SQ SI
WZRRBA S SI I
WZUJSD S I
XNXEE6 I S MULTIDRUG TEST
Y3AFEE S I I SI one step immonochromatographic assay
YFYCWJ S
YGKDY2 SI SI
YSKXXD S I
Z4YCUT I
ZGAWTE S I
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
1314
RESPONSE SUMMARY FOR TEST SAMPLE 1
Participants: 96
The response summary of all 96 participating laboratories for the identification of BS-1, frequency of use of screening and identification techniques and false positives and negatives:
Identification of Test Sample-1:
BS-1 was a blank test sample containing no substances from the ICE menu
False positives for Test Sample-1:
Round Code: Substance reported: Tech Code:
3FMD3X GHB 230
False negatives for Test Sample-1 (techniques(s) used for ANP):
Frequency of use of screening, identification and quantification techniques:
Response Summary
Participants 96
Technique 100 110 120 140 141 150 160 161 170 180 210
Screening (No.) 2 54 3 1 1 2 0 0 0 26 12
(%) 2.1 56.3 3.1 1.0 1.0 2.1 0.0 0.0 0.0 27.1 12.5
Identification (No.) 0 3 0 0 0 6 1 7 1 81 7
(%) 0.0 3.1 0.0 0.0 0.0 6.3 1.0 7.3 1.0 84.4 7.3
Quantification (No.) 0 1 0 0 0 0 1 4 0 28 2
(%) 0.0 1.8 0.0 0.0 0.0 0.0 1.8 7.0 0.0 49.1 3.5
1415
Identified substances for Test Sample 2
Code Identified Substances0H72WR Nordazepam and Amfetamine
1111EF OXAZEPAM, TEMAZEPAM, NORDAZEPAM, AMFETAMINE
1A3AXJ Oxazepam, Temazepam, Nordazepam and Amphethamine
35TZAW Amphétamine, Nordazepam, Oxazepam, Temazepam
3FMD3X Amphetamine, oxazepam, medazepam, nordazepam, temazepam, diazepam
4FF58F Amfetamine, Nordazepam, Oxazepam, Temazepam
66OQY6 amphetamine, nordiazepam, temazepam
6V10VI amfetamine, nordazepam, temazepam
7BVRLF amphetamines, benzodiazepines
7FEMIN Anfetamina, Temazepam, Nordiazepam
84HKVU Amfetamine, Nordazepam, Oxazepam,Temazepam
8LCBAB Amfetamine, Oxazepam, 4-Bromo-2,5-dimethoxyphenethylamine (2C-B)
8MFF1T BENZODIACEPINES AND ANPHETAMINES
8TPBUN Amfetamine, Nordazepam
8VX7GU Amphetamine, Nordiazepam, Temazepam, Oxazepam
AG3666 Amfetamine, Nordazepam, Temazepam, Oxazepam
AMMRSO Amfetamine, Nordazepam, Oxazepam, Temazepam
B1KV8H anfetamina, nordazepam
BBKEUE Amfetamine, Nordazepam, Oxazepam, Temazepam
BHWJHB Amphetamine, temazepam, nordiazepam, oxazepam
BNGG0M amphetamine, nardazepam, oxazepam, temazepam
CPUSPP Amfetamine; Nordazepam; Temazepam; Oxazepam
CTTCT3 amphetamine, nordiazepam,oxacepam,temazepam
D1AYDM Amfetamine, Nordazepam, Oxazepam, Temazepam
DB4Y6M AMPHETAMINE, NORDAZEPAM, OXAZEPAM, TEMAZEPAM
DDA5D2 amphetamine, nordazepam, oxazepam, temazepam
DDSBTD Amfetamine, Nordazepam,Oxazepam,Temazepam
DFYDDD Nordazepam, Oxazepam, Temazepam
DHUDIC Amphetamine, Oxazepam and Nordazepam
DQMUDL Amphetamine; Nordiazepam, Oxazepam, Temazepam
EPEVE2 Amfetamine, Nordazepam, Oxazepam, Temazepam
FBYTRU Amfetamine and Nordazepam
FWXVWL Amfetamine, Benzodiazepines and metabolites: Oxazepam, Temazepam, Nordazepam
GAHHTQ Amfetamine, Nordazepam
GBGZ1G Amphetamine and Nordazepam
GMUMBE Amphetamine, Nordiazepam, Oxazepam, Temazepam
GNAW99 Amfetamine
GUGPPP amfetamine,nordazepam,temazepam,oxazepam
GXJGYM nordazepam, temazepam, oxazepam, amphetamine
H2PHCD nordazepam, temazepam
Sample 2 Analysis
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
1516
Code Identified SubstancesHB4JKY amphetamines, benzodiazepam
HHLH88 Nordazepam, Temazepam, Delorazepam,Caffeine.
HVHHFH Amfetamine, Oxazepam, Temazepam and Nordazepam
IJS22F amfetamine, nordazepam, temazepam
IQIQAI Nordazepam, Temazepam, Amphetamine
IQJAM7 nordazepam, oxazepam
IVV5RV amphetamine
JRKD4U AMPHETAMINE,NORDAZEPAM,TEMAZEPAM,OXAZEPAM
JSZABT amfetamine, nordazepa, oxazepam, temazepam
K3KSJ9 Amfetamine, Nordiazepam and Temazepam
KHJBOK Amphetamine, Nordazepam, Temazepam
L3ZOZH Amfetamine, Temazepan, Nordazepam,oxacepam
LJTLFH Amphetamine & Nordazepam
M8VO1Z Amfetamine, Nordazepam, Oxazepam, Temazepam
MXA7O5 AMF and Benzos
NCMGK4 amphetamine, nordazepam and temazepam
NDP7T7 temazepam, nordazepam, oxazepam, amfetamine
NGAJ1Y Amphetamine, Nordazepam, Temazepam
NP5333 amfetamine,nordazepam,temazepam,oxazepam
OOO3GD amphetamine/nordazepam/temazepam
PCBAPT amfetamine
PQFUYI AMPHETAMINE, NORDIAZEPAM, OXAZEPAM, TEMAZEPAM
PXJDZ1 amphetamine,benzo
Q4WQSQ Amfetamine, Nordazepam, Temazepam, Oxazepam
QZEZZZ Amfetamine,Nordazepam,Oxazepam,Temazepam
RNJJ8Z anphetamine, nordazepam, temazepam, oxazepam
SOK66J Amphetamine, Nordiazepam, Oxazepam, Temazepam
SV8SSS Amphetamine, nordazepam, temazepam
SZZ1BZ amfetamine, nordazepam, temazepam, oxazepam
T0B0D0 Amfetamine, Nordazepam and Temazepam
TBORSX Amfetamine
TISIQZ Amphetamine ; nordiazepam ; oxazepam
TTTGKV oxazepam, camazepam,nordazepam and amphetamine
U5KOOL Amfetamine, nordiazepam, temazepam and oxazepam
UCTGCC Nordazepam, Oxazepam, Temazepam
UIUDEC amfetamine, nordazepam and temazepam
USDN2N Amphetamine, oxazepam, Nordazepam, Temazepam.
UTSOWL Amphetamine, Benzodiazepines
UUXUUM Amphetamine and Nordazepam
V6ZRMH Nordiazepam, amfetamine
VLHXHH amphetamine+ nordazepam
VN2UVV Nordazepam and Amfetamine
VR1QQH Amphetamine, Nordiazepam, Oxazepam, Temazepam
W5TXOT nordazepam
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
1617
Code Identified SubstancesWEB9SQ amfetamine, nordazepam,oxazepam,temazepam
WZRRBA Amfetamine, Nordazepam, Oxazepam and Temazepam
WZUJSD methamphetamine,nordazepam
XNXEE6 FOUND
Y3AFEE amphetamine, nordazepam, oxazepam, temazepam
YFYCWJ Benzodiacepinas
YGKDY2 Nordiazepam, temazepam and oxazepam
YSKXXD amfetamine, nordazepam, oxazepam, temazepam
Z4YCUT Amfetamine, Nordazepam, Oxazepam, Temazepam
ZGAWTE Amfetamine, Nordazepam and Temazepam.
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
1718
Code Amfetamine Nordazepam Oxazepam Temazepam
0H72WR + + - -
Nordazepam and Amfetamine Detected
1111EF + + + +
1A3AXJ + + + +
those drugs were identified by LC/MS/MS
35TZAW + + + +
3FMD3X + + + +
Amphetamine (2374.28 ng/mL), oxazepam (1270.68 ng/mL), medazepam (3643.41 ng/mL), nordazepam (3577.85 ng/mL), temazepam (not quantified) and diazepam (< 5.0 ng/mL) were detected in sample BS2 2017/1.
4FF58F + + + +
66OQY6 ANP ANP ANP ANP
6V10VI + + - +
7BVRLF + + - +
amphetamine, nordiazepam, temazepam
7FEMIN + + + +
84HKVU + + + +
The sample contains amfetamine, nordazepam, oxazepam and temazepam.
8LCBAB + - + -
We found: Amfetamine, Oxazepam, 4-Bromo-2,5-dimethoxyphenethylamine (2C-B)
8MFF1T - + - +
NORDAZEPAM AND TEMAZEPAM
8TPBUN + + - -
Amfetamine, Nordazepam
8VX7GU + + + +
AG3666 + + + +
Amfetamine, Nordazepam, Temazepam and Oxazepam were identified by GCMS analysis.
AMMRSO + + + +
Amfetamine, Nordazepam, Oxazepam, Temazepam were found in the sample 2017/1/BS-2
B1KV8H + + - -
positivo para anfetamina y nordazepam
BBKEUE + + + +
BHWJHB + + + +
Amphetamine was found in urine, indicationg intake of amphetamine or a drug that metabolizes to amphetamine. Amphetamine is a stimulating drug. Temazepam, nordiazepam and oxazepam was in addition found. All these drugs are metabolites of diazepam, and could be explained by intake of diazepam: as these drugs in addition can be taken as individual drugs a combination of intake can not be ruled out.
BNGG0M + + + +
In the sample were found: amphetamine, nardazepam, oxazepam, temazepam
Statement of findings for Test Sample 2
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
1819
Code Amfetamine Nordazepam Oxazepam Temazepam
CPUSPP + + + +
CTTCT3 + + + +
The presence of nordiazepam, oxacepam, temazepam in urine indicates consumption of diazepam, or the consumption of each of the benzodiacepines themselves. The presence of amphetamine in urine indicates the consumption of amphetamine by itself or the consumption of metanphetamine.
D1AYDM + + + +
Positive to amfetamine, nordazepam, oxazepam and temazepam.
DB4Y6M + + + +
DDA5D2 + + + +
presence of amphetamine and diazepam metabolites
DDSBTD + + + +
DFYDDD - + + +
In Sample 2017/1/BS-2 the drugs Nordazepam, Oxazepam, Temazepam were found.
DHUDIC + + + ANP
It was detected the presence of Amphetamine, Oxazepam and Nordazepam in the sample analysed.
DQMUDL + + + +
Amphetamine is a central nervous system stimulant, and is a Schedule II substance in the United States. Nordiazepam is a long acting benzodiazepine, and is a Schedule IV substance in the United States. Oxazepam is a short to intermediate acting benzodiazepine and is a Schedule IV substance in the United States. Temazepam is an intermediate acting benzodiazepine and is a Schedule IV drug in the United States. Nordiazepam, oxazepam and temazepam can all also be metabolites of Diazepam.
EPEVE2 + + + +
Sample is positive for Amfetamine, Nordazepam, Oxazepam, Temazepam
FBYTRU + + ANP ANP
Amfetamine and Nordazepam were detected in sample 2017/1/BS-2
FWXVWL + + + +
GAHHTQ + + ANP -
Amfetamine and Nordazepam were identified in the sample.
GBGZ1G + + ANP ANP
The sample tested positive for Amphetamine type stimulants and Benzodiazapines on screening. Creatinine levels were satisfactory.
Amphetamine was confirmed in the sample and quantified at 1198 ng/ml.
Nordazepam was confirmed in the sample, however no validated quantification procedure is in place at our laboratory therefore quantification was not done.
GMUMBE + + + +
Positive for amphetamine and benzodiazepines
GNAW99 + ANP ANP ANP
We found two other stains in TLC plate for this sample but becaus we did not have refrence drugs we could not identify them
GUGPPP + + + +
drugs detected
GXJGYM + + + +
a preliminar positive result for benzodiacepines and amphetamines in EIA. A confirmation for CG/MS and LC/QTOF
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
1920
Code Amfetamine Nordazepam Oxazepam Temazepam
H2PHCD ANP + ANP +
use of benzodiazepines (nordazepam, temazepam)
HB4JKY + + ANP +
amphetamine, temazepam, nordazepam
HHLH88 - + - +
Confirmed my GS/MS Method.
HVHHFH + + + +
Sample code number 2017/1/BS-2 was found to contain amfetamine (concentration 1189 ng/ml), oxazepam (concentration 647 ng/ml), temazepam (concentration 634 ng/ml) and nordazepam (concentration 2049 ng/ml).
IJS22F + + - +
IQIQAI + + ANP +
Amphetamine, nordazepam and temazepam detected.
IQJAM7 - + + ANP
IVV5RV + + + +
illegal drugs (amphetamine) and benzodiazepines (metabolites): nordazepam, oxazepam and temazepam. Caffeine present.
JRKD4U + + + +
THE SAMPLE BS-2 ANALYZED DOES CONTAINS AMPHETAMINE AND BENZODIAZEPINE METABOLITES ( NORDAZEPAM,TEMAZEPAM,OXAZEPAM)
JSZABT + + + +
Abuse of "speed". Use of medicinal drugs containing nordazepam and temazepam. Oxazepam is probably the metabolite of these two.
K3KSJ9 + + - +
2017/1/BS-2 found to contain 113 ng/ml of Amfetamine,1462.46 ng/ml of Nordiazepam and 389.8 ng/ml of Temazepam
KHJBOK + + - +
KJPKK4 ANP ANP ANP ANP
L3ZOZH + + + +
LJTLFH + + ANP ANP
The urine was analysed and found to contain Amphetamine and Nordazepam.
M8VO1Z + + + +
MXA7O5 + + + +
consumer of AMF and benzos
NCMGK4 + + - +
NDP7T7 + + + +
general extraction, identification and confirmation with HPLC/DAD, the curve was realised in different concentration
NGAJ1Y + + - +
NP5333 + + + +
amfetamine, nordazepam,temazepam,oxazepam were found in the sample BS-2 at the detection limit.
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
2021
Code Amfetamine Nordazepam Oxazepam Temazepam
OOO3GD + + ANP +
sample was spiked with amphetamine , nordazepam and temazepam
PCBAPT + + + +
nordazepam, oxazepam, temazepam, caffeine
PQFUYI + + + +
PXJDZ1 + - - -
Q4WQSQ + + + +
Screening test (EIA). Positive ; GC/MS: Relation m/z, time retention (tR ) the reference material Amfetamine, Nordazepam, Temazepam, Oxazepam are equivalents to those sample 2017/1/ BS-2
QZEZZZ + + + +
-
RNJJ8Z + + + +
SOK66J + + + +
Amphetamine ~ 0.7mg/LNordiazepam Detected > 1mg/LOxazepam ~ 0.5mg/LTemazepam ~0.5mg/L
SV8SSS + + - +
SZZ1BZ + + + +
Positive to amfetamine, nordazepam, temazepam, oxazepam.
T0B0D0 + + ANP +
Sample 2017/1/BS-2 found to contain Amfetamine, Nordazepam and Temazepam
TBORSX + + + +
Amfetamine,Oxazepam
TG33JW + + + -
TISIQZ + + + -
Analytical Adverse Finding for amphetamine, nordiazepam and oxazepam.
TTTGKV + + + -
by using CR & GC-MS techniques ( Oxazepam , Camazepam , Nordazepam ) were detected in urine sample.
by using LC-MS (Amphetamine) was detected.
U5KOOL + + + +
The presence of amphetamine in the urine sample shows previous use of the drug.The presence of nordiazepam, temazepam and oxazepam in the urine is consistent with previous use of diazepam.
UCTGCC ANP + + +
Nordazepam, Oxazepam, Temazepam were detected
UIUDEC + + - +
In urine sample number two was identified amfetamine, nordazepam and temazepam
USDN2N + + + +
The coincidence between the retention time and mass-fragmentogram from a reference standard, analyzed at the same conditions that the biological sample, indicates the presence of Amphetamine, oxazepam, Nordazepam and Temazepam in the biological sample.
UTSOWL + + - +
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
2122
Code Amfetamine Nordazepam Oxazepam Temazepam
UUXUUM + + ANP ANP
Amphetamine and Nordazepam detected in the sample
V6ZRMH + + - -
The presence of nordiazepam in urine indicates the use of diazepam or nordiazepam.The presence of amfetamine in urine indicates the use of amfetamine.
VLHXHH + + - -
after analysis performed the sample contained amphetamine +nordazepam+caffeine
VN2UVV + + ANP ANP
Nordazepam and Amfetamine were detected in BS-2 sample
VR1QQH + + + +
The urine sample screened positive for the presence of amphetamine, and also nordiazepam, oxazepam and temazepam (indicative of benzodiazepine consumption).
W5TXOT - + - -
The test sample 2017/1/BS-2 was found to contain the controlled drug nordazepam.
WEB9SQ + + + +
Detected: amphetamines, benzodiazepines
WZRRBA + + + +
Examination of the sample coded 2017/1/BS-2 revealed the presence of amphetamine, nordazepam, oxazepam and temazepam.
WZUJSD - + ANP ANP
2017/1/BS-2 contain methamphetamine, nordazepam
XNXEE6 + + + +
NORDAZEPAM, TEMAZEPAM, OXAZEPAM, ANFETAMINE
Y3AFEE + + + +
YFYCWJ ANP ANP ANP ANP
Positivo
YGKDY2 - + + +
Nordiazepam, temazepam and oxazepam were qualitatively reported as nordiazepam was above the upper limit of linearity in 2017/01/BS-02.
YSKXXD + + + +
In this sample amfetamine, nordazepam, oxazepam, temazepam were found, which indicates that person consumed amfetamine and diazepam.
Z4YCUT + + + +
ZGAWTE + + - +
It was detected Amfetamine, Temazepam and Nordazepam into 2017/1/BS-2 sample by Gas Chromatography/Mass Spectrometry (GC/MS).
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
2223
Identification methods for Test Sample 2
Code 100 110 120 140 141 150 160 161 170 180 230 231 210
0H72WR I
1111EF I I
1A3AXJ I S chemical immunochromatographic
35TZAW S I I
3FMD3X I SI S Dip test
4FF58F S I LC/QTOF
6V10VI S I I
7BVRLF S SI I
7FEMIN S I I
84HKVU SI I S Multi-Drug Screen Test Panel
8LCBAB I SI Dipro drug lab screen
8MFF1T S I
8TPBUN I SI I
8VX7GU S I I SI Kinetic Interaction of Microparticles in Solution
AG3666 S I
AMMRSO S SI S I
B1KV8H S I I
BBKEUE S I I
BHWJHB S SI S LC-QTOF
BNGG0M S I
CPUSPP S I I
CTTCT3 I I S inmunocromatografía flujo lateral
D1AYDM S I SI
DB4Y6M S I
DDA5D2 S SI SI
DDSBTD S SI I
DFYDDD SI SI
DHUDIC S I
DQMUDL I LC/TOF
EPEVE2 S SI S LC-TOF
FBYTRU SI
FWXVWL S SI I
GAHHTQ S SI I
Analytical Technique Codes
Legend: S ... used for Screening I ... used for Identification SI ... used for both
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
2324
Code 100 110 120 140 141 150 160 161 170 180 230 231 210
GBGZ1G S I
GMUMBE S SI
GNAW99 SI
GUGPPP SI
GXJGYM S I I LC-QTOF
H2PHCD I
HB4JKY S I
HHLH88 S I
HVHHFH SI I
IJS22F S I
IQIQAI S I
IQJAM7 S I
IVV5RV I I SI
JRKD4U SI SI
JSZABT I I S
K3KSJ9 S I
KHJBOK I I
KJPKK4 I S zivia kit multitest
L3ZOZH S I
LJTLFH S I
M8VO1Z S I SI
MXA7O5 SI
NCMGK4 SI
NDP7T7 I I S immunochromatographie
NGAJ1Y S I
NP5333 S SI
OOO3GD S I I
PCBAPT S I I
PQFUYI SI SI I
PXJDZ1 SI I I
Q4WQSQ S I
QZEZZZ SI
RNJJ8Z S I
SOK66J S I I
SV8SSS I SI
SZZ1BZ S I
T0B0D0 SI
TBORSX S I
TG33JW S I I
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
2425
Code 100 110 120 140 141 150 160 161 170 180 230 231 210
TISIQZ SI SI
TTTGKV S S I I
U5KOOL S I I
UCTGCC S I I
UIUDEC S I
USDN2N I
UTSOWL I I Triage 8- ALERE Sure Step
UUXUUM SI I
V6ZRMH S I SI
VLHXHH S I
VN2UVV S I
VR1QQH SI
W5TXOT SI
WEB9SQ SI
WZRRBA S SI I
WZUJSD S I
XNXEE6 I S MULTIDRUG TEST
Y3AFEE S I I SI one step immonochromatographic assay
YFYCWJ S
YGKDY2 SI SI
YSKXXD S I
Z4YCUT I
ZGAWTE S I
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
2526
RESPONSE SUMMARY FOR TEST SAMPLE 2
Participants: 96
The response summary of all 96 participating laboratories for the identification of BS-2, frequency of use of screening and identification techniques and false positives and negatives:
Identification of Test Sample-2:
Substance Name Number of laboratories correctly identifying:
Amfetamine 84
Nordazepam 90
Oxazepam 60
Temazepam 72
False positives for Test Sample-2:
Round Code: Substance reported: Tech Code:
3FMD3X Medazepam, Diazepam 230
8LCBAB 2C-B 150/Dipro screen
TTTGKV Camazepam N/A
WZUJSD Methamphetamine 150
TG33JW Tenamfetamine 231
KJPKK4 Methylecgonine 180
False negatives for Test Sample-2 (techniques(s) used for ANP):
Where none of the four components were identified or were not considered for analysis
Round Code: Answer Code: Tech Code:
66OQY6 ANP -
KJPKK4 ANP -
YFYGWJ ANP -
Frequency of use of screening, identification and quantification techniques:
Response Summary
Participants 96
Technique 100 110 120 140 141 150 160 161 170 180 210
Screening (No.) 2 54 3 1 1 2 0 0 0 26 12
(%) 2.1 56.3 3.1 1.0 1.0 2.1 0.0 0.0 0.0 27.1 12.5
Identification (No.) 0 3 0 0 0 6 1 7 1 81 7
(%) 0.0 3.1 0.0 0.0 0.0 6.3 1.0 7.3 1.0 84.4 7.3
Quantification (No.) 0 1 0 0 0 0 1 4 0 28 2
(%) 0.0 1.8 0.0 0.0 0.0 0.0 1.8 7.0 0.0 49.1 3.5
2627
Round: 2017/1Substance: BS-2; Amfetamine
Z-Score Report per Sample per Substance
Robust average = 1103 ng/ml
UNODC value = 1270 ng/ml
z-scores can be interpreted by participants in line with ISO 13528:2005, secion 7.4.2 and ISO/IEC guide43-1:1997(E) as follows:
IzI < 2 = satisfactory2 ≤ IzI ≤ 3 = questionable
IzI > 3 = unsatisfactory
According to the recommendations in ISO 13528:2005, an unsatisfactory z-score is considered to give an action signal and a questionable z-score is considered to give a warning signal. A single action signal or warning signal in two successive rounds shall be taken that an
anomaly has occured that requires inverstigation.
-6.1
-2.5
-1.5 -1.5
-1.3 -1.2
-0.9-0.8
-0.7 -0.6 -0.6 -0.6- 0.5
-0.3 -0.2-0.2
0.0
0.1 0.10.3 0.3
0.4 0.5 0.5 0.6 0.6 0.6 0.6 0.7 0.70.9 0.9
1.3
2.7
7.9 17.7
-4.0
-3.0
-2.0
-1.0
0.0
1.0
2.0
3.0
4.0
K3
KSJ
9
SOK
66J
Y3A
FEE
RN
JJ8
Z
8V
X7G
U
EPE
VE2
7FE
MIN
4FF
58F
QZE
ZZZ
TBO
RSX
DD
SBTD
BB
KEU
E
YSK
XX
D
BN
GG
0M
UTS
OW
L
BH
WJH
B
U5
KO
OL
D1
AYD
M
JSZA
BT
TG33
JW
AM
MR
SO
GU
GP
PP
8TP
BU
N
HV
HH
FH
FWX
VW
L
66O
QY6
GB
GZ1
G
M8
VO
1Z
DD
A5
D2
NP
5333
WZR
RB
A
MX
A7
O5
DB
4Y6
M
CP
USP
P
3FM
D3
X
VLH
XH
H
2728
Z-Score Report per Sample per Substance
Round: 2017/1Substance: BS-2; Amfetamine
-6
-4
-2
0
2
4
6
z-sc
ore
Dispersion of z-scores using different analytical techniques for the quantification of Amfetamine in 2017/1 BS-2
GC/MS LC/MS
2829
Round: 2017/1Substance: BS-2; Nordazepam
Z-Score Report per Sample per Substance
Robust average = 1840 ng/ml
UNODC value = 1960 ng/ml
z-scores can be interpreted by participants in line with ISO 13528:2005, secion 7.4.2 and ISO/IEC guide43-1:1997(E) as follows:
IzI < 2 = satisfactory2 ≤ IzI ≤ 3 = questionable
IzI > 3 = unsatisfactory
According to the recommendations in ISO 13528:2005, an unsatisfactory z-score is considered to give an action signal and a questionable z-score is considered to give a warning signal. A single action signal or warning signal in two successive rounds shall be taken that an anomaly has occured that requires inverstigation.
-5.1 -4.7
-2.1 -2.0
-1.2-1.1
-0.8 -0.7 -0.7 -0.7
-0.4-0.3 -0.3 -0.2 -0.2 -0.1 -0.1 0.0
0.10.2
0.4 0.5 0.5 0.5 0.6 0.6 0.6 0.7 0.8 0.8 0.8
1.8 1.8
3.1
5.6
-4.00
-3.00
-2.00
-1.00
0.00
1.00
2.00
3.00
4.00
GX
JGYM
IQJA
M7
DD
A5
D2
CP U
SPP
K3
KSJ
9
TBO
RSX
U5
KO
OL
BN
GG
0M
D1
AYD
M
8TP
BU
N
BB
KEU
E
WZR
RB
A
66O
QY6
EPEV
E2
DD
SBTD
MX
A7
O5
7FE
MIN
AM
MR
SO
DB
4Y6
M
TG33
JW
FWX
VW
L
JSZA
BT
8M
FF1
T
GU
GP
PP
M8
VO
1Z
RN
JJ8
Z
UTS
OW
L
HV
HH
FH
BH
WJH
B
YSK
XX
D
4FF
58F
Y3A
FEE
84H
KV
U
QZE
ZZZ
3FM
D3
X
2930
Z-Score Report per Sample per Substance
Round: 2017/1Substance: BS-2; Nordazepam
-6
-4
-2
0
2
4
6
z-sc
ore
Dispersion of z-scores using different analytical techniques for the quantification of Nordazepam in 2017/1 BS-2
GC/MSLC/MS
HPLC
3031
Round: 2017/1Substance: BS-2; Oxazepam
Z-Score Report per Sample per Substance
Robust average = 529 ng/ml
UNODC value = 570 ng/ml
z-scores can be interpreted by participants in line with ISO 13528:2005, secion 7.4.2 and ISO/IEC guide43-1:1997(E) as follows:IzI < 2 = satisfactory
2 ≤ IzI ≤ 3 = questionableIzI > 3 = unsatisfactory
According to the recommendations in ISO 13528:2005, an unsatisfactory z-score is considered to give an action signal and a questionable z-
score is considered to give a warning signal. A single action signal or warning signal in two successive rounds shall be taken that an anomaly has occured that requires inverstigation.
-4.5
-1.6
-1.1 - 1.0
- 0.9 - 0.8-0.7
-0.6-0.5
-0.4 -0.3 -0.3 -0.3 -0.3 -0.2 -0.2
0.4 0.4 0.40.6
0.80.9 0.9
1.3
2.1
7.9 8.9 43.1
-4.00
-3.00
-2.00
-1.00
0.00
1.00
2.00
3.00
4.00
GX
JGYM
CP
USP
P
BN
GG
0M
7F E
MIN
TG33
JW
JSZA
BT
D1
AYD
M
U5
KO
OL
BH
WJH
B
DD
SBTD
DD
A5
D2
GU
GP
PP
TBO
RSX
AM
MR
SO
SOK
66J
EPEV
E2
4FF
58F
MX
A7
O5
BB
KEU
E
M8
VO
1Z
QZE
ZZZ
FWX
VW
L
DB
4Y6
M
HV
HH
FH
84H
KV
U
3FM
D3
X
IQJA
M7
Y3A
FEE
3132
Z-Score Report per Sample per Substance
Round: 2017/1Substance: BS-2; Oxazepam
-6
-4
-2
0
2
4
6
z-sc
ore
Dispersion of z-scores using different analytical techniques for the quantification of Oxazepam in 2017/1 BS-2
GC/MSLC/MS
HPLC
3233
Round: 2017/1Substance: BS-2; Temazepam
Z-Score Report per Sample per Substance
Robust average = 530 ng/ml
UNODC value = 580 ng/ml
z-scores can be interpreted by participants in line with ISO 13528:2005, secion 7.4.2 and ISO/IEC guide43-1:1997(E) as follows:
IzI < 2 = satisfactory
2 ≤ IzI ≤ 3 = questionableIzI > 3 = unsatisfactory
According to the recommendations in ISO 13528:2005, an unsatisfactory z-score is considered to give an action signal and a quest ionable z-score is considered to give a warning signal. A single action signal or warning signal in two successive rounds shall be taken that an
anomaly has occured that requires inverstigation.
-3.0
-2.4
-1.2 -1.2
-1.0-0.9 - 0.9
-0.8-0.6
-0.3 -0.3 - 0.3 -0.3 -0.3-0.2
0.1 0.1 0.1 0.1 0.2 0.20.4
0.7 0.70.8
0.9 0.9
1.5
1.71.9
4.7
-4.00
-3.00
-2.00
-1.00
0.00
1.00
2.00
3.00
4.00
GX
JGYM
UT
SOW
L
CP
USP
P
K3
KSJ
9
BN
GG
0M
TG33
JW
D1
AYD
M
66O
QY6
DD
A5
D2
BB
KEU
E
AM
MR
SO
SOK
66J
TBO
RSX
QZE
ZZZ
GU
GP
PP
EPEV
E2
U5
KO
OL
FWX
VW
L
DB
4Y6
M
DD
SBTD
M8
VO
1Z
BH
WJH
B
4FF
58F
8M
FF1
T
JSZA
BT
HV
HH
FH
7FE
MIN
WZR
RB
A
84H
KV
U
Y3A
FEE
ND
P7T
7
3334
Z-Score Report per Sample per Substance
Round: 2017/1Substance: BS-2; Temazepam
-6
-4
-2
0
2
4
6
z-sc
ore
Dispersion of z-scores using different analytical techniques for the quantification of Temazepam in 2017/1 BS-2
GC/MS LC/MSHPLC
3435
Z-Scores for Test Sample 2
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
Concentration (ng/ml)
Deviation from
robust
average
z-score
K3KSJ9 113 -990 -6.1
SOK66J 695 -408 -2.5
Y3AFEE 854 -249 -1.5
RNJJ8Z 860 -243 -1.5
8VX7GU 901 -202 -1.3
EPEVE2 912 -191 -1.2
7FEMIN 957 -146 -0.9
4FF58F 967 -136 -0.8
QZEZZZ 995 -108 -0.7
TBORSX 1000 -103 -0.6
DDSBTD 1009 -94 -0.6
BBKEUE 1010 -93 -0.6
YSKXXD 1020 -83 -0.5
BNGG0M 1050 -53 -0.3
UTSOWL 1064 -39 -0.2
BHWJHB 1076 -27 -0.2
U5KOOL 1100 -3 0.0
D1AYDM 1115 12 0.1
JSZABT 1122 19 0.1
TG33JW 1145 42 0.3
AMMRSO 1147 44 0.3
GUGPPP 1170 67 0.4
8TPBUN 1181 78 0.5
HVHHFH 1189 86 0.5
FWXVWL 1194 91 0.6
66OQY6 1197 94 0.6
GBGZ1G 1198 95 0.6
M8VO1Z 1201 98 0.6
DDA5D2 1209 106 0.7
NP5333 1223 120 0.7
WZRRBA 1240 137 0.9
MXA7O5 1252 149 0.9
DB4Y6M 1305 202 1.3
CPUSPP 1532 429 2.7
3FMD3X 2374 1271 7.9
VLHXHH 3950 2847 17.7
Code
Amfetamine
Concentration (ng/ml)
Deviation from
robust
average
z-score
GXJGYM 265 -1575 -5.1
IQJAM7 404 -1436 -4.7
DDA5D2 1206 -634 -2.1
CPUSPP 1232 -608 -2.0
K3KSJ9 1462 -378 -1.2
TBORSX 1500 -340 -1.1
U5KOOL 1600 -240 -0.8
BNGG0M 1625 -215 -0.7
D1AYDM 1626 -214 -0.7
8TPBUN 1638 -202 -0.7
BBKEUE 1710 -130 -0.4
WZRRBA 1750 -90 -0.3
66OQY6 1757 -83 -0.3
EPEVE2 1774 -66 -0.2
DDSBTD 1787 -53 -0.2
MXA7O5 1801 -39 -0.1
7FEMIN 1807 -33 -0.1
AMMRSO 1826 -14 0.0
DB4Y6M 1878 38 0.1
TG33JW 1914 74 0.2
FWXVWL 1975 135 0.4
JSZABT 1987 147 0.5
8MFF1T 1989 149 0.5
GUGPPP 2000 160 0.5
M8VO1Z 2017 177 0.6
RNJJ8Z 2028 188 0.6
UTSOWL 2028 188 0.6
HVHHFH 2049 209 0.7
BHWJHB 2071 231 0.8
YSKXXD 2085 245 0.8
4FF58F 2094 254 0.8
Y3AFEE 2385 545 1.8
84HKVU 2407 567 1.8QZEZZZ 2800 960 3.1
3FMD3X 3578 1738 5.6
Code
Nordazepam
3536
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
Concentration (ng/ml)
Deviation from
robust
average
z-score
GXJGYM 110 -419 -4.5
CPUSPP 376 -153 -1.6
BNGG0M 425 -104 -1.1
7FEMIN 432 -97 -1.0
TG33JW 448 -81 -0.9
JSZABT 450 -79 -0.8
D1AYDM 460 -69 -0.7
U5KOOL 470 -59 -0.6
BHWJHB 485 -44 -0.5
DDSBTD 496 -33 -0.4
DDA5D2 499 -30 -0.3
GUGPPP 500 -29 -0.3
TBORSX 500 -29 -0.3
AMMRSO 502 -27 -0.3
SOK66J 510 -19 -0.2
EPEVE2 510 -19 -0.2
4FF58F 565 36 0.4
MXA7O5 569 40 0.4
BBKEUE 570 41 0.4
M8VO1Z 585 56 0.6
QZEZZZ 600 71 0.8
FWXVWL 613 84 0.9
DB4Y6M 615 86 0.9
HVHHFH 647 118 1.3
84HKVU 729 200 2.1
3FMD3X 1271 742 7.9
IQJAM7 1368 839 8.9
Y3AFEE 4575 4046 43.1
Oxazepam
Code Concentration (ng/ml)
Deviation from
robust
average
z-score
GXJGYM 180 -350 -3.0
UTSOWL 248 -282 -2.4
CPUSPP 386 -144 -1.2
K3KSJ9 390 -140 -1.2
BNGG0M 410 -120 -1.0
TG33JW 419 -111 -0.9
D1AYDM 420 -110 -0.9
66OQY6 437 -93 -0.8
DDA5D2 462 -68 -0.6
BBKEUE 490 -40 -0.3
AMMRSO 494 -36 -0.3
SOK66J 496 -34 -0.3
TBORSX 500 -30 -0.3QZEZZZ 500 -30 -0.3
GUGPPP 508 -22 -0.2
EPEVE2 538 8 0.1
U5KOOL 540 10 0.1
FWXVWL 541 11 0.1
DB4Y6M 542 12 0.1
DDSBTD 549 19 0.2
M8VO1Z 555 25 0.2
BHWJHB 576 46 0.4
4FF58F 608 78 0.7
8MFF1T 608 78 0.7
JSZABT 622 92 0.8
HVHHFH 634 104 0.9
7FEMIN 640 110 0.9
WZRRBA 700 170 1.5
84HKVU 733 203 1.7
Y3AFEE 747 217 1.9
NDP7T7 1073 543 4.7
Code
Temazepam
3637
Identified substances for Test Sample 3
Code Identified Substances35TZAW GHB
3FMD3X None
4FF58F GHB
84HKVU gamma-Hydroxybutyric acid (GHB)
8LCBAB none
8VX7GU GHB
AG3666 gamma-Hydroxybutyric acid (GHB)
AMMRSO gamma-Hydroxybutyric acid (GHB)
BBKEUE GHB
BHWJHB GHB
BNGG0M gamma-Hydroxybutyric acid (GHB)
CPUSPP gamma-Butyrolactone (GBL)
D1AYDM gamma-Hydroxybutyric acid (GHB)
DDA5D2 GHB
DDSBTD -
DFYDDD None
EPEVE2 gamma-Hydroxybutyric acid (GHB)
FWXVWL gamma-Hydroxybutyric acid (GHB)
GBGZ1G NA
GUGPPP gamma-Hydroxybutyric acid
HVHHFH GHB
JSZABT GHB
KHJBOK no
M8VO1Z GHB
MXA7O5 no
NCMGK4 GHB
NDP7T7 GBL
NP5333 GHB
PCBAPT no drugs found
PQFUYI GHB
Q4WQSQ Not present
QZEZZZ gamma-Hydroxybutyric acid (GHB)
RNJJ8Z GHB
SOK66J GHB
SV8SSS morphin
T0B0D0 None
TTTGKV none
USDN2N NONE
UUXUUM GHB
VLHXHH GHB
Sample 3 Analysis
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
3738
Code Identified SubstancesVR1QQH Morphine - indicative
WEB9SQ gamma-hydroxybutyric-acid
WZRRBA gamma-hydroxybutyric acid
WZUJSD -
XNXEE6 FOUND
Y3AFEE GHB
YSKXXD GHB
Z4YCUT gamma-Hydroxybutyric acid (GHB)
ZGAWTE Ibuprofen and Cocaine
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
3839
Code gamma-Hydroxybutyric acid (GHB)
0H72WR -
Drugs Not Detected
1111EF ANP
1A3AXJ ANP
35TZAW +
3FMD3X -
No drugs were detected in sample BS3 2017/1.
4FF58F +
66OQY6 ANP
6V10VI -
7BVRLF ANP
7FEMIN ANP
84HKVU +
The sample contains gamma-Hydroxybutyric acid (GHB).
8LCBAB ANP
We did not find any drugs. We found only caffein.
8MFF1T -
8TPBUN -
8VX7GU +
AG3666 +
gamma-Hydroxybutyric acid (GHB) was identified by GCMS analysis.
AMMRSO +
gamma-Hydroxybutyric acid (GHB) was found in the sample 2017/1/BS-3
B1KV8H ANP
BBKEUE +
BHWJHB +
GHB was found in urine. GHB is a CNS depressant.
BNGG0M +
in the sample is detected gamma-Hydroxybutyric acid (GHB)
CPUSPP -
Statement of findings for Test Sample 3
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
3940
Code gamma-Hydroxybutyric acid (GHB)
CTTCT3 ANP
D1AYDM +
Positive to gamma-hydroxybutyric acid (GHB).
DB4Y6M ANP
BLANK
DDA5D2 +
Presence of GHB
DDSBTD ANP
-
DFYDDD ANP
In Sample 2017/1/BS-3 no drug was found
DHUDIC ANP
The substances that were tested for weren´t found to be present in the sample analysed.
DQMUDL ANP
EPEVE2 +
Sample is positive for gamma-Hydroxybutyric acid (GHB)
FBYTRU ANP
No common drugs were detected in sample 2017/1/BS-3
FWXVWL +
GAHHTQ ANP
GBGZ1G ANP
Sample was negative during screening for all drug groups tested at our laboratory. Creatinine levels were satisfactory.
GMUMBE ANP
Negative
GNAW99 ANP
GUGPPP +
drugs detected
GXJGYM ANP
a preliminar screenning by EIA with no possitive results
H2PHCD ANP
HB4JKY ANP
HHLH88 -
Performed by GS/MS Method and Caffeine was found.
HVHHFH +
Sample code number 2017/1/BS-3 was found to contain gamma-Hydroxybutyric acid (concentration 15980 ng/ml)
IJS22F ANP
IQIQAI ANP
Common drugs not detected.
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
4041
Code gamma-Hydroxybutyric acid (GHB)
IQJAM7 ANP
IVV5RV ANP
(remark : caffeine, nicotine en quinine present)
JRKD4U ANP
THE SAMPLE BS-3 ANALYZED DOES NOT CONTAINS CONTROLLED DRUGS ( AMPHETAMINE, BENZODIAZEPINES,COCAINE/METABOLITES,OPIATES,11-NOR-DELTA9-THC-9-CARBOXYLIC ACID,BARBITURATES.
JSZABT +
Abuse of GBL or GHB or 1,4-butanediol.
K3KSJ9 -
KHJBOK ANP
KJPKK4 ANP
L3ZOZH ANP
ibuprofen positive
LJTLFH ANP
M8VO1Z +
MXA7O5 -
blank sample
NCMGK4 +
NDP7T7 -
general extraction, identification and confirmation with GC/MS
NGAJ1Y ANP
NP5333 +
gamma-Hydroxybutyric acid was found in the sample BS-3 at the detection limit.
OOO3GD ANP
no drugs were found
PCBAPT -
caffeine, ibuprophen,aripiprazole
PQFUYI +
PXJDZ1 -
Q4WQSQ ANP
Screening test, GC/MS,: Not to be present.
QZEZZZ +
-
RNJJ8Z +
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
4142
Code gamma-Hydroxybutyric acid (GHB)
SOK66J +
GHB ~ 23mg/L
SV8SSS -
SZZ1BZ ANP
Negative.
T0B0D0 ANP
Sample 2017/1/BS-3 found not to contain any drugs
TBORSX +
gamma-Hydroxybutyric acid (GHB)
TG33JW +
TISIQZ ANP
Negative in the screening method
TTTGKV ANP
no control drugs found
U5KOOL ANP
UCTGCC ANP
UIUDEC ANP
No drug was found in the sample number 3
USDN2N ANP
UTSOWL ANP
UUXUUM +
GHB detected in the sample
V6ZRMH ANP
VLHXHH +
after analysis performed the sample contained GHB +CAFFEINE
VN2UVV ANP
Drugs were not detected in BS-3 sample
VR1QQH ANP
The urine sample screened indicative for the presence of morphine.
W5TXOT ANP
No controlled drugs of the ICE 2017/1 menu were detected in the test sample 2017/1/BS-3.
WEB9SQ +
other
WZRRBA +
Examination of the sample coded 2017/1/BS-3 revealed the presence of gamma-hydroxybutyric acid (GHB).
WZUJSD ANP
negative
XNXEE6 +
GHB
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
4243
Code gamma-Hydroxybutyric acid (GHB)
Y3AFEE +
YFYCWJ ANP
No se detectó
YGKDY2 ANP
No controlled drug from ICE 2017/01 menu is detected
YSKXXD +
In this sample GHB was found, which indicates that person consumed GHB.
Z4YCUT +
ZGAWTE ANP
It was detected Ibuprofen and Cocaine into 2017/1/BS-3 sample by Gas Chromatography/Mass Spectrometry (GC/MS).
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
4344
Identification methods for Test Sample 3
Code 100 110 120 140 141 150 160 161 170 180 230 231 210
0H72WR I
1111EF I I
1A3AXJ I S chemical immunochromatographic
35TZAW S I I
3FMD3X I SI S Dip test
4FF58F S I LC/QTOF
6V10VI S I I
7BVRLF S SI I
7FEMIN S I I
84HKVU SI I S Multi-Drug Screen Test Panel
8LCBAB I SI Dipro drug lab screen
8MFF1T S I
8TPBUN I SI I
8VX7GU S I I SI Kinetic Interaction of Microparticles in Solution
AG3666 S I
AMMRSO S SI S I
B1KV8H S I I
BBKEUE S I I
BHWJHB S SI S LC-QTOF
BNGG0M S I
CPUSPP S I I
CTTCT3 I I S inmunocromatografía flujo lateral
D1AYDM S I SI
DB4Y6M S I
DDA5D2 S SI SI
DDSBTD S SI I
DFYDDD SI SI
DHUDIC S I
DQMUDL I LC/TOF
EPEVE2 S SI S LC-TOF
FBYTRU SI
FWXVWL S SI I
GAHHTQ S SI I
Analytical Technique Codes
Legend: S ... used for Screening I ... used for Identification SI ... used for both
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
4445
Code 100 110 120 140 141 150 160 161 170 180 230 231 210
GBGZ1G S I
GMUMBE S SI
GNAW99 SI
GUGPPP SI
GXJGYM S I I LC-QTOF
H2PHCD I
HB4JKY S I
HHLH88 S I
HVHHFH SI I
IJS22F S I
IQIQAI S I
IQJAM7 S I
IVV5RV I I SI
JRKD4U SI SI
JSZABT I I S
K3KSJ9 S I
KHJBOK I I
KJPKK4 I S zivia kit multitest
L3ZOZH S I
LJTLFH S I
M8VO1Z S I SI
MXA7O5 SI
NCMGK4 SI
NDP7T7 I I S immunochromatographie
NGAJ1Y S I
NP5333 S SI
OOO3GD S I I
PCBAPT S I I
PQFUYI SI SI I
PXJDZ1 SI I I
Q4WQSQ S I
QZEZZZ SI
RNJJ8Z S I
SOK66J S I I
SV8SSS I SI
SZZ1BZ S I
T0B0D0 SI
TBORSX S I
TG33JW S I I
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
4546
Code 100 110 120 140 141 150 160 161 170 180 230 231 210
TISIQZ SI SI
TTTGKV S S I I
U5KOOL S I I
UCTGCC S I I
UIUDEC S I
USDN2N I
UTSOWL I I Triage 8- ALERE Sure Step
UUXUUM SI I
V6ZRMH S I SI
VLHXHH S I
VN2UVV S I
VR1QQH SI
W5TXOT SI
WEB9SQ SI
WZRRBA S SI I
WZUJSD S I
XNXEE6 I S MULTIDRUG TEST
Y3AFEE S I I SI one step immonochromatographic assay
YFYCWJ S
YGKDY2 SI SI
YSKXXD S I
Z4YCUT I
ZGAWTE S I
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
4647
RESPONSE SUMMARY FOR TEST SAMPLE 3
Participants: 96
The response summary of all 96 participating laboratories for the identification of BS-3, frequency of use of
screening and identification techniques and false positives and negatives:
Identification of Test Sample-3:
Substance Name Number of laboratories correctly identifying:
GHB 33
False positives for Test Sample-3:
Round Code: Substance reported: Tech Code:
SV8SSS Morphine 150/180
VR1QQH Morphine 231
ZGAWTE Cocaine 180
CPUSPP GBL 180
KJPKK4 MDMA 180
NDP7T7 GBL 180
False negatives for Test Sample-3 (techniques(s) used for ANP):
Round Code: Answer Code: Tech Code: K3KSJ9 - 231
6V10VI - 231
8MFF1T - 180
HHLH88 - 180
MXA7O5 - 180
3FMD3X - 180
Round Code: Answer Code: Tech Code: 0H72WR - 180
PXJDZ1 - 110
PCBAPT - 180
CPUSPP - 150
8TPBUN - 231
NDP7T7 - 180
Forty nine laboratories did not carry out analysis for GHB in test sample 3
Frequency of use of screening, identification and quantification techniques:
Response Summary
Participants 96
Technique 100 110 120 140 141 150 160 161 170 180 210
Screening (No.) 2 54 3 1 1 2 0 0 0 26 12
(%) 2.1 56.3 3.1 1.0 1.0 2.1 0.0 0.0 0.0 27.1 12.5
Identification (No.) 0 3 0 0 0 6 1 7 1 81 7
(%) 0.0 3.1 0.0 0.0 0.0 6.3 1.0 7.3 1.0 84.4 7.3
Quantification (No.) 0 1 0 0 0 0 1 4 0 28 2
(%) 0.0 1.8 0.0 0.0 0.0 0.0 1.8 7.0 0.0 49.1 3.5
SV8SSS - 180/231
4748
Round: 2017/1Substance: BS-3; GHB
Z-Score Report per Sample per Substance
Robust average = 17382 ng/ml
UNODC value = 16560 ng/ml
z-scores can be interpreted by participants in line with ISO 13528:2005, secion 7.4.2 and ISO/IEC guide43-1:1997(E) as follows:
IzI < 2 = satisfactory2 ≤ IzI ≤ 3 = questionable
IzI > 3 = unsatisfactory
According to the recommendations in ISO 13528:2005, an unsatisfactory z-score is considered to give an action signal and a quest ionable z-score is considered to give a warning signal. A single action signal or warning signal in two successive rounds shall be taken that an anomaly has occured that requires inverstigation.
-1.7
-1.3
-0.9
-0.6 -0.6 -0.5 -0.5 -0.4 -0.4
-0.2 -0.2 -0.1
0.4
0.9
1.1
1.9
2.2
3.3
6.5
-4.00
-3.00
-2.00
-1.00
0.00
1.00
2.00
3.00
4.00
JSZA
BT
BN
GG
0M
TG33
JW
D1
AYD
M
BH
WJH
B
GU
GP
PP
HV
HH
FH
EPEV
E2
35T
ZAW
BB
KEU
E
M8
VO
1Z
QZE
ZZZ
FWX
VW
L
TBO
RSX
RN
JJ8
Z
SOK
66J
AM
MR
SO
DD
A5
D2
Y3A
FEE
4849
Z-Score Report per Sample per Substance
Round: 2017/1Substance: BS-3; GHB
-6
-4
-2
0
2
4
6
z-sc
ore
Dispersion of z-scores using different analytical techniques for the quantification of GHB in 2017/1 BS-3
GC/MS LC/MS
4950
Z-Scores for Test Sample 3
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
Concentration
(ng/ml)
Deviation from
robust averagez-score
JSZABT 12340 -5042 -1.7
BNGG0M 13500 -3882 -1.3
TG33JW 14763 -2619 -0.9
D1AYDM 15500 -1882 -0.6
BHWJHB 15615 -1767 -0.6
GUGPPP 15840 -1542 -0.5
HVHHFH 15980 -1402 -0.5
EPEVE2 16060 -1322 -0.4
35TZAW 16100 -1282 -0.4
BBKEUE 16850 -532 -0.2
M8VO1Z 16908 -474 -0.2
QZEZZZ 17000 -382 -0.1
FWXVWL 18700 1318 0.4
TBORSX 20000 2618 0.9
RNJJ8Z 20760 3378 1.1
SOK66J 23200 5818 1.9
AMMRSO 24000 6618 2.2
DDA5D2 27400 10018 3.3
Y3AFEE 37101 19719 6.5
Code
GHB
5051
Identified substances for Test Sample 4
Code Identified Substances0H72WR Morphine and 6-MAM
1111EF MORPHINE
1A3AXJ Morphine, Hydromorphone
35TZAW Morphine
3FMD3X Morphine
4FF58F Morphine
66OQY6 morphine
6V10VI morphine
7BVRLF opiates
7FEMIN Morphine
84HKVU Morphine
8LCBAB Opiates
8MFF1T MORPHINE
8TPBUN Morphine
8VX7GU Morphine
AG3666 Morphine
AMMRSO Morphine
BBKEUE Morphine
BHWJHB Morphine
BNGG0M Morphine (Total)
CPUSPP Morphine
CTTCT3 Morphine
D1AYDM Morphine (total)
DB4Y6M MORPHINE
DDA5D2 morphine
DDSBTD Morphine
DFYDDD Morphine
DHUDIC Morphine
DQMUDL Morphine
EPEVE2 Morphine
FWXVWL Morphine
GAHHTQ Morphine, 11-nor-delta9- THC-9-carboxylic acid
GBGZ1G Morphine
GMUMBE Morphine
GNAW99 Morphine
GUGPPP Morphine
GXJGYM MORPHINE
H2PHCD morphine
HB4JKY opiates
HHLH88 Morphine, Caffeine, Ibuprofen, Umbelliferone.
Sample 4 Analysis
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
5152
Code Identified SubstancesHVHHFH Morphine
IJS22F morphine
IQIQAI Morphine, 6-MAM
IQJAM7 morphine
IVV5RV morphine
JRKD4U MORPHINE
JSZABT morphine
K3KSJ9 morphine
KHJBOK no
M8VO1Z Morphine
MXA7O5 MOR
NCMGK4 morphine
NDP7T7 NONE
NGAJ1Y Morphine, 6-Monoacetylmorphine (6-MAM)
NP5333 morphine
OOO3GD morphine
PCBAPT morphine
PQFUYI MORPHINE
PXJDZ1 opiates , opioids
Q4WQSQ Morphine
QZEZZZ Morphine (Total)
RNJJ8Z morphine
SOK66J Morphine (Total)
SV8SSS morphin, codeine
SZZ1BZ morphine
T0B0D0 None
TBORSX Morphine
TISIQZ Morphine
TTTGKV Morphine
U5KOOL Morphine
UCTGCC Morphine
UIUDEC morphine
USDN2N Morphine
UTSOWL Morphine
UUXUUM Morphine
V6ZRMH Morphine
VLHXHH MORPHINE
VN2UVV Morphine and 6-Monoacetylmorphine (6-MAM)
VR1QQH Morphine
WEB9SQ morphine
WZRRBA Morphine
WZUJSD morphine-3-O-glucuronide
XNXEE6 FOUND
Y3AFEE morphine
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
5253
Code Identified SubstancesYFYCWJ Morfina
YGKDY2 Morphine
YSKXXD morphine
Z4YCUT Morphine
ZGAWTE Not detected.
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
5354
Code Morphine (Total)
0H72WR +
Morphine and 6-MAM Detected
1111EF +
1A3AXJ +
Those drugs were identified by LC/MS/MS
35TZAW +
3FMD3X +
Morphine (1563.45 ng/mL) was detected in sample BS4 2017/1.
4FF58F +
66OQY6 ANP
Free morphine was measured
6V10VI +
7BVRLF +
moprhine
7FEMIN +
84HKVU +
The sample contains morphine.
8LCBAB +
We found: Morphine total and Codeine
8MFF1T +
NO COMMENTS
8TPBUN +
Morphine
8VX7GU +
AG3666 +
Morphine was identified by GCMS analysis.
AMMRSO +
Morphine was found in the sample 2017/1/BS-4
B1KV8H -
BBKEUE +
BHWJHB +
Morphine is detected in urine. This indicates intake of morphine, or heroine which is metabolized to morphine in the body. Morphine is an analgesic opiate.
BNGG0M +
in the sample is detected Morphine (Total)
CPUSPP +
Statement of findings for Test Sample 4
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
5455
Code Morphine (Total)
CTTCT3 +
The presence of morphine in urine indicates morphine consumption or other drugs such as heroin and codeine.
D1AYDM +
Positive to morphine.
DB4Y6M +
DDA5D2 +
Presence of morphine
DDSBTD +
DFYDDD +
In Sample 2017/1/BS-4 the drug morphine was found.
DHUDIC +
It was detected the presence of Morphine in the sample analysed.
DQMUDL +
Morhphine is a narcotic analgesic found in the opium poppy. It is a Schedule II substance in the United States.
EPEVE2 +
Sample is positive for Morphine
FBYTRU ANP
No common drugs were detected in sample 2017/1/BS-4
FWXVWL +
GAHHTQ +
Morphine and 11-nor-delta9- THC-9-carboxylic acid were identified in the sample.
GBGZ1G +
The sample was positive for opiates on screening. Creatinine levels were satisfactory.
The presence of Morphine was confirmed and quantified at 1114 ng/ml. The sample was also negative for Codeine, eliminating Codeine intake as a source of the Morphine in Urine.
GMUMBE +
Positive for opiates
GNAW99 +
GUGPPP +
drugs detected
GXJGYM +
Preliminar positive results by EIA for opiods/ opiates confirmated by CG/MS and LC/QTOF
H2PHCD +
use of morphine
HB4JKY +
morphine
HHLH88 +
Confirmed my GS/MS Method.
HVHHFH +
Sample code number 2017/1/BS-4 was found to contain morphine (concentration 839 ng/ml)
IJS22F +
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
5556
Code Morphine (Total)
IQIQAI +
Morphine and 6-MAM detected.
IQJAM7 +
IVV5RV +
(remark :caffeine present)
JRKD4U +
THE SAMPLE BS-4 ANALYZED DOES CONTAINS AN OPIATE ( MORPHINE).
JSZABT +
Abuse of pure heroin or morphine or use of medicinal morphine.
K3KSJ9 +
2017/1/BS-4 found to contain 190.7 ng/ml of Morphine
KHJBOK -
KJPKK4 ANP
L3ZOZH +
paracetamol positive
LJTLFH ANP
M8VO1Z +
MXA7O5 +
opioid consumer
NCMGK4 +
NDP7T7 -
NGAJ1Y +
NP5333 +
morphin was found in the sample BS-4 at the detection limit.
OOO3GD +
PCBAPT +
caffeine, acetaminophen
PQFUYI +
PXJDZ1 +
Q4WQSQ +
Screening test (EIA). Positive. GC/MS: Relation m/z, time retention (tR ) the reference material Morphine are equivalents to those sample 2017/1 /BS-4
QZEZZZ +
-
RNJJ8Z +
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
5657
Code Morphine (Total)
SOK66J +
Morphine, Total Detected > 0.5mg/L
SV8SSS +
SZZ1BZ +
Positive to morphine.
T0B0D0 ANP
Sample 2017/1/BS-4 found not to contain any drugs
TBORSX +
Morphine
TG33JW +
TISIQZ +
Analytical Adverse Finding for Morphine (free) with a concentration of 0,9 µg/ml
TTTGKV +
by using CR & GC-MS techniques ( Morphine ) was detected in urine sample.
U5KOOL +
The presence of morphine in the urine sample shows previous use of the drug.
UCTGCC +
Morphine was detected
UIUDEC +
In urine sample number four was identified morphine
USDN2N +
The coincidence between the retention time and mass-fragmentogram from a reference standard, analyzed at the same conditions that the biological sample, indicates the presence of Morphine in the biological sample.
UTSOWL +
UUXUUM +
Morphine detected in the sample
V6ZRMH +
The presence of morphine in urine indicates the use of morphine
VLHXHH +
after analysis performed the sample contained MOAPHINE + CAFFEINE
VN2UVV +
Morphine and 6-Monoacetylmorphine (6-MAM) were detected in BS-4 sample
VR1QQH +
The urine sample screened positive for the presence of morphine.
W5TXOT -
No controlled drugs of the ICE 2017/1 menu were detected in the test sample 2017/1/BS-4.
WEB9SQ +
Detected: opiates
WZRRBA +
Examination of the sample coded 2017/1/BS-4 revealed the presence of morphine.
WZUJSD -
2017/1/BS-4 contain opiates.
XNXEE6 +
MORPHINE
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
5758
Code Morphine (Total)
Y3AFEE +
YFYCWJ ANP
Positivo
YGKDY2 +
Morphine was qualitatively reported as morphine was above the upper limit of linearity in 2017/01/BS-04.
YSKXXD +
In this sample morphine was found, which indicates that person consumed morphine.
Z4YCUT +
ZGAWTE ANP
Not detected drugs into 2017/1/BS-4 sample by Gas Chromatgraphy/Mass Spectrometry (CG/MS).
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
5859
Identification methods for Test Sample 4
Code 100 110 120 140 141 150 160 161 170 180 230 231 210
0H72WR I
1111EF I I
1A3AXJ I S chemical immunochromatographic
35TZAW S I I
3FMD3X I SI S Dip test
4FF58F S I LC/QTOF
6V10VI S I I
7BVRLF S SI I
7FEMIN S I I
84HKVU SI I S Multi-Drug Screen Test Panel
8LCBAB I SI Dipro drug lab screen
8MFF1T S I
8TPBUN I SI I
8VX7GU S I I SI Kinetic Interaction of Microparticles in Solution
AG3666 S I
AMMRSO S SI S I
B1KV8H S I I
BBKEUE S I I
BHWJHB S SI S LC-QTOF
BNGG0M S I
CPUSPP S I I
CTTCT3 I I S inmunocromatografía flujo lateral
D1AYDM S I SI
DB4Y6M S I
DDA5D2 S SI SI
DDSBTD S SI I
DFYDDD SI SI
DHUDIC S I
DQMUDL I LC/TOF
EPEVE2 S SI S LC-TOF
FBYTRU SI
FWXVWL S SI I
GAHHTQ S SI I
Analytical Technique Codes
Legend: S ... used for Screening I ... used for Identification SI ... used for both
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
5960
Code 100 110 120 140 141 150 160 161 170 180 230 231 210
GBGZ1G S I
GMUMBE S SI
GNAW99 SI
GUGPPP SI
GXJGYM S I I LC-QTOF
H2PHCD I
HB4JKY S I
HHLH88 S I
HVHHFH SI I
IJS22F S I
IQIQAI S I
IQJAM7 S I
IVV5RV I I SI
JRKD4U SI SI
JSZABT I I S
K3KSJ9 S I
KHJBOK I I
KJPKK4 I S zivia kit multitest
L3ZOZH S I
LJTLFH S I
M8VO1Z S I SI
MXA7O5 SI
NCMGK4 SI
NDP7T7 I I S immunochromatographie
NGAJ1Y S I
NP5333 S SI
OOO3GD S I I
PCBAPT S I I
PQFUYI SI SI I
PXJDZ1 SI I I
Q4WQSQ S I
QZEZZZ SI
RNJJ8Z S I
SOK66J S I I
SV8SSS I SI
SZZ1BZ S I
T0B0D0 SI
TBORSX S I
TG33JW S I I
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
6061
Code 100 110 120 140 141 150 160 161 170 180 230 231 210
TISIQZ SI SI
TTTGKV S S I I
U5KOOL S I I
UCTGCC S I I
UIUDEC S I
USDN2N I
UTSOWL I I Triage 8- ALERE Sure Step
UUXUUM SI I
V6ZRMH S I SI
VLHXHH S I
VN2UVV S I
VR1QQH SI
W5TXOT SI
WEB9SQ SI
WZRRBA S SI I
WZUJSD S I
XNXEE6 I S MULTIDRUG TEST
Y3AFEE S I I SI one step immonochromatographic assay
YFYCWJ S
YGKDY2 SI SI
YSKXXD S I
Z4YCUT I
ZGAWTE S I
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
6162
RESPONSE SUMMARY FOR TEST SAMPLE 4
Participants: 96
The response summary of all 96 participating laboratories for the identification of BS-4, frequency of use of
screening and identification techniques and false positives and negatives:
Identification of Test Sample-4:
Substance Name Number of laboratories correctly identifying:
Morphine 84
False positives for Test Sample-4:
Round Code: Substance Name: Tech Code:
OH72WR 6-Monoacetylmorphine 180
GAHHTQ delta-9-THC acid 180
IQIQAI 6-Monoacetylmorphine 180
NGAJ1Y 6-Monoacetylmorphine 180
SV8SSS Codeine 180
VN2UVV 6-Monoacetylmorphine 180
WZUJSP Morphine 3-glucuronide 150
PXJDZI Morphine 3-glucuronide, Codeine 180
8LCBAB Codeine 150
False negatives for Test Sample-4 (techniques(s) used for ANP):
Round Code: Substance Name: Tech Code:
B1KV8H - 150
W5TXOT - 180
NDP7T7 - 180
WZUJSD - 150
KHJBOK - 150
FBYTRU
ANP
ZGAWTE
ANP
KJPKK4 ANP
T0B0D0 ANP
LJTLFH ANP
Frequency of use of screening, identification and quantification techniques:
Response Summary
Participants 96
Technique 100 110 120 140 141 150 160 161 170 180 210
Screening (No.) 2 54 3 1 1 2 0 0 0 26 12
(%) 2.1 56.3 3.1 1.0 1.0 2.1 0.0 0.0 0.0 27.1 12.5
Identification (No.) 0 3 0 0 0 6 1 7 1 81 7
(%) 0.0 3.1 0.0 0.0 0.0 6.3 1.0 7.3 1.0 84.4 7.3
Quantification (No.) 0 1 0 0 0 0 1 4 0 28 2
(%) 0.0 1.8 0.0 0.0 0.0 0.0 1.8 7.0 0.0 49.1 3.5
6263
Z-Score Report per Sample per Substance
Round: 2017/1 Robust average = 822 ng/ml
Substance: BS-4; Morphine UNODC value = 860 ng/ml
z-scores can be interpreted by participants in line with ISO 13528:2005, secion 7.4.2 and ISO/IEC guide43-1:1997(E) as follows:IzI < 2 = satisfactory
2 ≤ IzI ≤ 3 = questionableIzI > 3 = unsatisfactory
According to the recommendations in ISO 13528:2005, an unsatisfactory z -score is considered to give an action signal and a questionable z-
score is considered to give a warning signal. A single action signal or warning signal in two successive rounds shall be taken that an anomaly has occured that requires inverstigation.
-3.4
-2.3
-1.4 - 1.4 -1.3-1.2
-1.0 -0.9-0.7
-0.6 -0.6-0.5 -0.5
- 0.4- 0.3 - 0.3
-0.2-0.1
0.0 0.0 0.0
0.0 0.1 0.2 0.20.3
0.4 0.4 0.5 0.60.7
1.6
2.1
2.62.8
3.4
4.0
6.5 14.3
-4.00
-3.00
-2.00
-1.00
0.00
1.00
2.00
3.00
4.00
K3
KSJ
9
UTS
OW
L
CP
USP
P
8TP
BU
N
GX
JGYM
QZE
ZZZ
8V
X7
GU
66O
QY6
JSZA
BT
BH
WJH
B
D1
AYD
M
EPEV
E2
7FE
MIN
Y3A
FEE
DD
SBTD
YSK
XX
D
BN
GG
0M
TBO
RSX
TG33
JW
DD
A5
D2
M8
VO
1Z
GU
GP
PP
HV
HH
FH
AM
MR
SO
NP
5333
BB
KEU
E
TISI
QZ
FWX
VW
L
IQJA
M7
DB
4Y6
M
4FF
58F
GB
GZ1
G
84H
KV
U
MX
A7
O5
8M
FF1
T
RN
JJ8
Z
3FM
D3
X
VLH
XH
H
WZR
RB
A
6364
Z-Score Report per Sample per Substance
Round: 2017/1Substance: BS-4; Morphine
-6
-4
-2
0
2
4
6
z-sc
ore
Dispersion of z-scores using different analytical techniques for the quantification of Morphine in 2017/1 BS-4
GC/MS LC/MS
6465
Z-Scores for Test Sample 4
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
Concentration
(ng/ml)
Deviation from
robust averagez-score
K3KSJ9 191 -631 -3.4
UTSOWL 398 -424 -2.3
CPUSPP 553 -269 -1.4
8TPBUN 564 -258 -1.4
GXJGYM 570 -252 -1.3
QZEZZZ 600 -222 -1.2
8VX7GU 639 -183 -1.066OQY6 656 -166 -0.9
JSZABT 685 -137 -0.7
BHWJHB 710 -112 -0.6
D1AYDM 710 -112 -0.6
EPEVE2 725 -97 -0.5
7FEMIN 728 -94 -0.5
Y3AFEE 750 -72 -0.4
DDSBTD 769 -53 -0.3
YSKXXD 769 -53 -0.3
BNGG0M 780 -42 -0.2
TBORSX 800 -22 -0.1
TG33JW 817 -5 0.0
DDA5D2 821 -1 0.0
M8VO1Z 821 -1 0.0
GUGPPP 831 9 0.0
HVHHFH 839 17 0.1
AMMRSO 850 28 0.2
NP5333 852 30 0.2
BBKEUE 880 58 0.3TISIQZ 900 78 0.4
FWXVWL 902 80 0.4
IQJAM7 914 92 0.5
DB4Y6M 932 110 0.6
4FF58F 958 136 0.7
GBGZ1G 1114 292 1.6
84HKVU 1221 399 2.1
MXA7O5 1311 489 2.6
8MFF1T 1339 517 2.8
RNJJ8Z 1461 639 3.4
3FMD3X 1563 741 4.0
VLHXHH 2035 1213 6.5
WZRRBA 3500 2678 14.3
Code
Morphine
6566
The Laboratory and Scientific SectionUNODC, International CentreWagramer Strasse 5, P.O. Box 500A-1400, Vienna, AUSTRIAEmail: [email protected]
2017/1-BS Copyright (c) 2017 UNODC
INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP)INTERNATIONAL COLLABORATIVE EXERCISES (ICE)
6667